129 related articles for article (PubMed ID: 17302532)
1. Clinical activity of tipifarnib in hematologic malignancies.
Jabbour E; Kantarjian H; Cortes J
Expert Opin Investig Drugs; 2007 Mar; 16(3):381-92. PubMed ID: 17302532
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
5. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Cortes J
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S30-5. PubMed ID: 14556673
[TBL] [Abstract][Full Text] [Related]
9. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
10. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Karp JE
Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
[TBL] [Abstract][Full Text] [Related]
11. Tipifarnib: farnesyl transferase inhibition at a crossroads.
Mesa RA
Expert Rev Anticancer Ther; 2006 Mar; 6(3):313-9. PubMed ID: 16503848
[TBL] [Abstract][Full Text] [Related]
12. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
[TBL] [Abstract][Full Text] [Related]
13. In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors.
Kotsianidis I; Bazdiara I; Anastasiades A; Spanoudakis E; Pantelidou D; Margaritis D; Bourikas G; De Coster R; De Porre P; Tsatalas C
Acta Haematol; 2008; 120(1):51-6. PubMed ID: 18824842
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inhibitors: where are we now?
Tsimberidou AM; Chandhasin C; Kurzrock R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Dombi E; Gillespie A; Wolters PL; Belasco J; Goldman S; Korf BR; Solomon J; Martin S; Salzer W; Fox E; Patronas N; Kieran MW; Perentesis JP; Reddy A; Wright JJ; Kim A; Steinberg SM; Balis FM
Neuro Oncol; 2014 May; 16(5):707-18. PubMed ID: 24500418
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R
Blood; 2007 May; 109(10):4158-63. PubMed ID: 17264294
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib.
Xue X; Lai KT; Huang JF; Gu Y; Karlsson L; Fourie A
J Pharmacol Exp Ther; 2006 Apr; 317(1):53-60. PubMed ID: 16352705
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
Lancet JE; Karp JE
Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
[TBL] [Abstract][Full Text] [Related]
20. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
